WO2001026646A1 - PRODUITS NUTRACEUTIQUES CONTENANT SAMe AINSI QUE DES SUPPLEMENTS ALIMENTAIRES ET LEUR PROCEDE DE FABRICATION ET D'UTILISATION - Google Patents

PRODUITS NUTRACEUTIQUES CONTENANT SAMe AINSI QUE DES SUPPLEMENTS ALIMENTAIRES ET LEUR PROCEDE DE FABRICATION ET D'UTILISATION Download PDF

Info

Publication number
WO2001026646A1
WO2001026646A1 PCT/US2000/027559 US0027559W WO0126646A1 WO 2001026646 A1 WO2001026646 A1 WO 2001026646A1 US 0027559 W US0027559 W US 0027559W WO 0126646 A1 WO0126646 A1 WO 0126646A1
Authority
WO
WIPO (PCT)
Prior art keywords
same
weight percent
product
nutraceutical product
derivative
Prior art date
Application number
PCT/US2000/027559
Other languages
English (en)
Other versions
WO2001026646A8 (fr
Inventor
Larry Howard
Original Assignee
Pharmnseas, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmnseas, Inc. filed Critical Pharmnseas, Inc.
Priority to AU78634/00A priority Critical patent/AU7863400A/en
Publication of WO2001026646A1 publication Critical patent/WO2001026646A1/fr
Publication of WO2001026646A8 publication Critical patent/WO2001026646A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/77—Sapindaceae (Soapberry family), e.g. lychee or soapberry
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/16—Ginkgophyta, e.g. Ginkgoaceae (Ginkgo family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
    • A61K36/296—Epimedium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/67—Piperaceae (Pepper family), e.g. Jamaican pepper or kava
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/75—Rutaceae (Rue family)
    • A61K36/752—Citrus, e.g. lime, orange or lemon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/84—Valerianaceae (Valerian family), e.g. valerian
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • SAMe S-adenosyl-L-methionine, and its salts, (either or both herein referred to as SAMe) are well known pharmacologically active compositions that combat depression, arthritis, and liver diseases such as, for example, cirrhosis.
  • SAMe occurs as two diastereoisomers: (RS)- (+)-SAMe and (SS)-(+)-SAMe.
  • the (SS)-(+)-SAM-e diastereoisomer is the pharmacologically active diastereoisomer, and SAMe products containing (SS)-(+)-SAMe at a concentration of at least 95 weight percent (%) of the total diastereoisomers mixture are known.
  • a suitable source of SAMe including the SAMe with the higher concentration of the (SS)-(+)-SAMe diastereoisomer, is Gnosis S. r. 1. of Milan, Italy. SUMMARY OF THE INVENT
  • This invention is a nutraceutical product comprising a blend of SAMe and one or more dietary supplements.
  • This nutraceutical product may be used by both humans and animals. Different nutraceutical products are provided having multiple beneficial properties.
  • the dietary supplements enhance the beneficial effects of the SAMe, or provide additional beneficial effects, or both.
  • the nutraceutical products of this invention preferably employ SAMe with the higher concentration of the (SS)-(+)-SAMe diastereoisomer.
  • the nutraceutical products of this invention may be administered by any conventional route such as, for example, oral, rectal, nasal, topical, or pareateral as tablets, caplets, softgel pills, capsules, suspensions, emulsions, solutions, suppositories, sprays, gums, drops, lozenges, or injectibles They may be sold either in bulk to companies that repackage the product for the consumer or in a form suitable for use directly by the consumer.
  • the nutraceutical products of this invention are in the form of a softgel pill, caplet, capsule or tablet.
  • the softgel pill, caplet, capsule or tablet is treated with a time release agent.
  • An enteric coating and/or micro-encapsulation may be employed to achieve time release, and one suitable time release agent is an aqueous ethyl cellulose dispersion sold under the trademark Surelease® by Colorcon, Inc. of Santa Ana, California.
  • Packaging of the nutraceutical products of this invention is important. As discussed subsequently in greater detail, moisture adversely affects SAMe. Retailers of nutraceutical products usually conduct accelerated aging tests by subjecting the packaged product to high temperatures and high humidity over a controlled time duration, measuring the SAMe concentration in the product before and after testing. It has been discovered that the softgel pill, caplet, capsule or tablet form of the nutraceutical products of this invention completely enclosed and sealed within an aluminum foil package resist degradation.
  • the softgel pill, caplet, capsule or tablet is first completely enclosed within a plastic wrap and then completely enclosed and sealed the aluminum foil.
  • the aluminum foil package acts as a moisture barrier, enabling said softgel pill, caplet, capsule or table to have substantially prolonged life when subjected to accelerated testing than a softgel pill, caplet, capsule or table contained within, for example, a sealed bottle or plastic blister pack.
  • the thickness of the aluminum foil is from 2 to 6 mils.
  • the nutraceutical products of this invention may also be sold in forms other than a softgel pill, caplet, capsule or tablet. For example these products may be used as topical applications such as creams, gels, patches, etc. They may also be in liquid form especially when used as an injectibles, or even as an enemas.
  • the following dietary supplements are used:
  • Co-Q-10 Coenzyme Q-10
  • St. John's Wort derivative either powder or any form of extract
  • Ginkgo Biloba derivative either powder or any form of extract
  • Ma Huang derivative either powder or any form of extract
  • Epimeduim pinnatum derivative either powder or extract
  • Guarana derivative either leaf or root powder or any form of extract
  • Citrus Aurantium derivative either powder or any from of extract
  • Kava Kava derivative either powder or any form of extract
  • cetyl myristoleate (CMO) cetyl myristoleate blended with cetyl oleate, cetyl esters and cetyl myristate
  • Valerian derivative either powder or any form of extract
  • glutathione fructose - 1,6 - diphosphate (FDP), glucosamine sulfate, glucosamine HCL, or glucosamine potassium, methyl sulfanyl methane (MSM), melatonin, hydrolyzed collagen, chondroitin sul
  • any one, or combinations of two or more, of these dietary supplements are mixed with SAMe, preferably with the SAMe comprising from about 0.1 to about 99 weight percent and the dietary supplement comprising from about 1 to about 99 weight percent of the nutraceutical product.
  • SAMe decomposes in the presence of water and high temperatures. This presents a problem when blending with dietary supplements.
  • conditions are controlled so that the moisture content of the product is less than 5 weight percent, preferably less than 3 weight percent. In some instances this may require drying the dietary supplements prior to blending with the SAMe.
  • the SAMe and dietary supplement or supplements being mixed with the SAMe are dry powders having a mesh ranging from about 60 to about 90.
  • the humidity of the manufacturing environment of nutraceutical product is less than 25% and the temperature of the manufacturing environment of nutraceutical product is from 20 to 15 degrees Celsius.
  • the nutraceutical product is encapsulated within capsules within 2 hours after manufacture. Preferably, these capsules are enteric coated, or otherwise treat with a time release agent, within 2 hours after encapsulation.
  • This invention also includes a method of supplementing a diet b y administering for at least 10 to 14 days SAMe at a dosage of from 800 to 1200 milligrams per day and at the same time administering a nutraceutical product comprising SAMe and a dietary supplement, said nutraceutical product including a a dosage of at least 400 milligrams p er day of SAMe, and after 14 days administering only said nutraceutical product.
  • the preferred stress reduction compositions of this invention preferably include a combination of SAMe and other natural stress reducing substances in effective amounts for maintaining and/or improving emotional and physical health during periods of stress.
  • One preferred embodiment of this invention especially effective in reducing emotional and physical stress and improving the ability to cope with such stress is SAMe in combination with one or more of the following: a Kava Kava derivative and a Valerian derivative.
  • SAMe is administered in dosages ranging from 10 mg to 2000 mg per day. Most preferably, SAMe is present in an amount of 400 mg per total daily dose which is to be taken one to two times per day.
  • Kava Kava extract is derived from a tropical plant found in the tropical regions of the Pacific rim and is known and used for its benefit of relieving symptoms of stress and anxiety, and to promote and induce relaxation.
  • a Kava Kava extract preferably 1-70% b y weight active ingredient, is present in an amount ranging from 10 mg to 2000 mg per dose per day.
  • a 30% by weight active ingredient Kava Kava extract is present in an amount of 600 mg per total daily dose taken one to two times.
  • Valerian Extract Another composition which is effective in providing health benefits in the form of stress reduction and/or coping is Valerian Extract.
  • Valerian is an herbal product known for its anti-anxiety and stress benefits and is sometimes used to help promote sleep.
  • a Valerian Root extract When used in combination with SAMe, a Valerian Root extract, preferably .8-30% by weight active ingredient is present in an amount ranging from 10 m g to 2000 mg per dose per day.
  • a 0.8% by weight Valerian Root extract is present in an amount of 100 mg per total daily dose taken one to two times per day.
  • compositions are to combine all of the above: 200 mg SAMe with 600 mg Kava Kava extract, and 100 mg Valerian root extract within a time-release or enteric coated capsule, caplet, or tablet along with standard inert ingredients utilized in the art. This composition to be taken one to two times per day.
  • Preferred Dosages 200 mg SAMe with 600 mg Kava Kava extract, and 100 mg Valerian root extract.
  • the preferred weight reduction and energy enhancement compositions of this invention preferably include a combination of SAMe and one or more other natural appetite suppressant and/or energy enhancing substances in effective amounts for this purpose.
  • One preferred embodiment of this invention especially effective for weight control and energy enhancement is SAMe in combination with one or more of the following: a Ma Huang derivative, a Epimedium Pinnatum derivative, a Citrus Aurantium derivative, and a Guarana derivative. These substances suppress appetite and increase energy. These substances provide weight reduction benefits by speeding up the body' s metabolism, thus increasing the body's ability to burn fat without exercise and enhance energy levels.
  • Component Weight Percentage SAMe about 5% to about 90% Ma Huang Extract 1-8% Activity about 5% to about 90% Epimedium Extract 1-50% Activity about 5% to about 90% Citrus Aruantium Extract 1-40% Activity about 5% to about 90% Guarana Extract 1-50% Activity about 5% to about 90%
  • SAMe is present in an amount ranging from 10 mg to 2000 mg per day. Preferably SAMe is present in an amount of 400 mg per day two times per day. Other weight loss benefit compositions may be taken with SAMe.
  • Another composition that is effective in providing health benefits in the form of weight reduction is Ma Huang.
  • Ma Huang is a naturally occurring herb which contains as an active weight reduction ingredient the sympathomimetic compound Ephedra Sinica, or its extract ephedrine. When used in combination with SAMe, Ma Huang Extract, preferably at a concentration of 1-8% by weight Activity, is present in an amount ranging from 10 mg to 2000 mg per dose per day.
  • a 6% by weight Ma Huang extract is present in an amount of 300 mg per daily dose taken two times per day before morning and evening meal.
  • Another composition which is effective in providing health benefits in the form of weight reduction is Epimedium Pinnatum Extract.
  • Epimedium Extract is known to increase energy levels and metabolism.
  • SAMe Session Initiation
  • Epimedium Extract preferably at a concentration of 1-50% by weight Activity is present in an amount ranging from 10 mg to 2000 mg per dose.
  • a 10% by weight Epimedium Pinnatum extract is present in an amount of 100 mg per daily dose taken two times per day before morning and evening meal.
  • Another composition which is effective in providing health benefits in the form of weight reduction is Citrus Aurantium Extract.
  • Citrus Aurantium Extract is known to increase energy levels and metabolism.
  • a 1-40% by weight Activity concentration of Citrus Aurantium Extract is present in a n amount ranging from 10 mg to 2000 mg per daily dose.
  • a 4% by weight Citrus Aurandum extract is present in an amount of 1 00 mg per dose taken two times per day before morning and evening meal.
  • Another composition which is effective in providing health benefits in the form of weight reduction is Guarana Extract.
  • Guarana Extract is known to increase energy levels and metabolism.
  • a 1-50% by weight Activity concentration of Guarana is present in an amount ranging from 10 mg to 2000 mg daily per dose.
  • a 10% by weight caffeine Guarana extract is present in an amount of 80 mg per dose taken two times per day.
  • Another preferred composition is to combine all of the above for an average daily dosage as follows: 200 mg to 400 mg SAMe with 900 mg Ma Huang Extract, 200 mg Epimedium Pinnatum Extract, 100 m g Citrus Aurantium Extract and 100 mg Guarana Extract within a time- release coated capsule or tablet along with standard inert ingredients utilized in the art.
  • Another preferred composition is to combine all of the above: 400 mg SAMe with 300 mg Ma Huang Extract, 100 mg Epimedium Pinnatum Extract, 100 mg Citrus Aurantium Extract and 80mg Guarana Extract within a time-release coated capsule or tablet along with standard inert ingredients utilized in the art; said composition to be taken two times per day before morning and evening meal.
  • the preferred anti-inflammation compositions of this invention preferably include a combination of SAMe and other natural anti-inflammatory substances in effective amounts for this purpose.
  • One preferred embodiment of this invention especially effective for inflammation reduction and joint pain is SAMe in combination with one or more of the following: methyl sulfanyl methane, cetyl myristoleate, glucosamine sulfate, glucosamine HCL, or glucosamine potassium, and hydrolyzed collagen. These components are known to help (a) relieve symptoms of arthritis and inflammation, (b) rebuild connective tissue, and (c) relieve symptoms related to sport injury and accidents affecting joints. There is a benefit to be found in taking these substances in combination, which increases the overall health benefit to joints over that obtained by taking each substance individually.
  • the following are the preferred weight percentage ranges of these anti-inflammation compositions:
  • SAMe is administered in an amount ranging from 10 mg to 2000 mg per day.
  • SAMe is present in an amount ranging from 400 mg to 800 mg per day.
  • SAMe is present in an amount of l OOmg per dose which is to be taken two to three times per day.
  • Other joint benefit compositions may be taken with SAMe.
  • MSM methyl sulfanyl methane
  • MSM is known to reduce symptoms caused by arthritis and sport injuries.
  • MSM is present in an amount ranging from 1 0 mg to 5000 mg per daily dose.
  • MSM is present in an amount of 300 mg per dose taken two times per day.
  • Another composition which is effective in providing health benefits to joints is cetyl myristoleate. Cetyl mysristoleate is known to help symptoms of rhumotoid arthritis and inflammation. When used in combination with SAMe, a 1-99% by weight concentration of cetyl myristoleate is present in an amount ranging from 0.5 mg to 2000 m g per dose per day.
  • an 20% by weight concentration of cetyl mysristoleate is present in an amount of 50 mg per dose taken two times per day.
  • Another composition which is effective in providing health benefits to joints is glucosamine sulfate, glucosamine HCL, or glucosamine potassium. This composition is known to help rebuild connective tissues and to ease symptoms of arthritis, injury, and inflammation.
  • glucosamine sulfate, glucosamine HCL, or glucosamine potassium is present in an amount ranging from 10 mg to 2000 mg per dose per day.
  • glucosamine sulfate, glucosamine HCL, or glucosamine potassium is present in an amount of 1000 mg per dose taken two to three times per day.
  • Another preferred composition is to combine all of the above: 1 00 mg SAMe with 300 mg MSM, 50 mg CMO, and 1000 mg glucosamine sulfate within a time-release coated capsule or tablet along with standard inert ingredients utilized in the art; said composition to b e taken one to four times per day.
  • Another preferred composition is to combine all of the above: about 400 mg SAMe with about 1000 mg MSM, with about 75 mg cetyl myristoleate, with about 1,000 mg glucosamine sulfate, with about 100 mg hydrolyzed collagen within a time-release coated capsule or tablet.
  • the preferred mind and mood enhancement compositions of this invention preferably include a combination of SAMe and other natural mind and mood substances in effective amounts for this purpose.
  • One preferred embodiment of this invention especially effective for mind and mood enhancement is SAMe in combination with one or more of the following: a St. John's Wort derivative and a Ginko Biloba derivative.
  • These emotional balance and brain function compositions are presented in a variety of formulations, with or without other emotional balance and/or brain function ingredients.
  • the herbal treatment composition preferably includes the desired combination of natural mood and brain function promoting substances in effective amounts for maintaining and/or improving emotional balance and/or memory and/or brain function.
  • quantity and dosage are intended to be specific examples and are not intended to limit the scope of the invention.
  • the following are the preferred weight percentage ranges of these mind and mood enhancement compositions:
  • Component Weight Percentage SAMe about 5% to about 90% St. John's Wort .1-50% about 5% to about 90% Ginkgo Biloba 1-99% about 5% to about 90%
  • SAMe is administered in an amount ranging from 10 mg to 2000 mg per day.
  • SAMe is used in an amount 400 mg per day.
  • SAMe is used in an amount of 400 mg per daily dose which is to be taken one to two times per day.
  • Another composition which is effective in providing health benefits in the form of increased emotional balance is St. John's Wort.
  • St. John's Wort is a naturally occurring herb which contains the therapeutically active ingredient hypericin and hyperforin. These ingredients have an anti-depressive effect which is believed to b e caused by modifying serotonin levels in the brain.
  • St John's Wort When used in combination with SAMe, St John's Wort, preferably a concentration between .1-50% by weight, is used in an amount ranging from 10 mg to 5000 mg per dose per day. Preferably a 0.3% by weight hypericin concentration of St. John's Wort extract is used in an amount of 900 m g per daily dose taken two times per day.
  • Another composition that is effective in providing health benefits in the form of improving memory and brain function as well as acting a s an anti-depressant is Ginko Biloba.
  • Ginko Biloba When used in combination with SAMe, Ginko Biloba, preferably a concentration between 1-99% b y weight, is used in an amount ranging from 0.5 mg to 2000 mg per dose per day.
  • a 24/6% by weight Ginko Biloba extract is used in an amount of 60 mg per daily dose.
  • Another preferred composition is to combine all of the above: 200 to 400 mg SAMe with 60 mg Ginko Biloba Extract, and 900 mg St. John' s Wort extract within a time-released coated capsule or tablet along with standard inert ingredients utilized in the art; said composition to b e taken one to two times per day.
  • Another preferred composition is to combine all of the above: lOOmg SAMe with 60 mg Ginko Biloba Extract, and 900 mg St. John's Wort extract within a time-released coated capsule or tablet along with standard inert ingredients utilized in the art; said composition to b e taken one to two times per day.
  • the present invention may be formulated for administration b y any conventional route including but not limited to oral, rectal, nasal, topical, or pareateral.
  • the composition may take the form of tablets, capsules, suspensions, emulsions, solutions, suppositories, sprays or injectibles, but is not limited to these forms.
  • the preferred liver enhancement and anti-oxidant compositions of this invention preferably include a combination of SAMe and other natural liver enhancement and anti-oxidant substances in effective amounts for this purpose.
  • One preferred embodiment of this invention especially effective as a liver enhancement and anti-oxidant is SAMe in combination with one or more of the following: Coenzyme Q-10, glutathione, and frutose - 1,6 - diphosphate.
  • Coenzyme Q-10 Coenzyme Q-10, glutathione, and frutose - 1,6 - diphosphate.
  • frutose - 1,6 - diphosphate frutose - 1,6 - diphosphate.
  • Component Weight Percentage SAMe about 5% to about 90%
  • Coenzyme Q-10 about 5% to about 90%
  • Glutathione about 5% to about 90%
  • Frutose - 1,6 - diphosphate about 5% to about 90%
  • the preferred sleep enhancement compositions of this invention preferably include a combination of SAMe and a natural sleep enhancement substances in effective amounts for this purpose.
  • One preferred embodiment of this invention especially effective a sleep enhancement product is SAMe in combination with one or more of the following: melatonin and a Kava Kava derivative. The following are the preferred weight percentage ranges of these sleep enhancement compositions:

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Emergency Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un produit nutraceutique contient un mélange de SAMe (S-adénosyl-L-méthionine) et d'un supplément alimentaire, la teneur en humidité du produit étant inférieure à 5 % en poids. Un produit nutraceutique préféré contient un mélange de diastéréoisomères (RS)-(+)-SAMe et (SS)-(+)-SAMe, le diastéréoisomère (SS)-(+)-SAMe se trouvant à une concentration d'au moins 95 % en poids du mélange.
PCT/US2000/027559 1999-10-08 2000-10-06 PRODUITS NUTRACEUTIQUES CONTENANT SAMe AINSI QUE DES SUPPLEMENTS ALIMENTAIRES ET LEUR PROCEDE DE FABRICATION ET D'UTILISATION WO2001026646A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU78634/00A AU7863400A (en) 1999-10-08 2000-10-06 Nutraceutical products containing same and dietary supplements and method of manufacture and use thereof

Applications Claiming Priority (10)

Application Number Priority Date Filing Date Title
US15832999P 1999-10-08 1999-10-08
US15848299P 1999-10-08 1999-10-08
US15832899P 1999-10-08 1999-10-08
US15848099P 1999-10-08 1999-10-08
US15829899P 1999-10-08 1999-10-08
US60/158,329 1999-10-08
US60/158,482 1999-10-08
US60/158,480 1999-10-08
US60/158,328 1999-10-08
US60/158,298 1999-10-08

Publications (2)

Publication Number Publication Date
WO2001026646A1 true WO2001026646A1 (fr) 2001-04-19
WO2001026646A8 WO2001026646A8 (fr) 2001-05-17

Family

ID=27538570

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/027559 WO2001026646A1 (fr) 1999-10-08 2000-10-06 PRODUITS NUTRACEUTIQUES CONTENANT SAMe AINSI QUE DES SUPPLEMENTS ALIMENTAIRES ET LEUR PROCEDE DE FABRICATION ET D'UTILISATION

Country Status (2)

Country Link
AU (1) AU7863400A (fr)
WO (1) WO2001026646A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092112A1 (fr) * 2001-05-11 2002-11-21 Holford & Associates Limited Supplement oral
WO2003013549A2 (fr) * 2001-08-09 2003-02-20 Degussa Food Ingredients Gmbh Formulation contenant de la (lyso-)phosphatidylserine, servant a prevenir et a traiter des etats de stress chez des homeothermes
WO2003041742A1 (fr) * 2001-11-13 2003-05-22 Rudolph Cartwright Composition nutraceutique
WO2003043608A1 (fr) * 2001-11-22 2003-05-30 Gnosis Srl Procede de preparation de tablettes comprenant de la s-adenosylmethionine
EP1690533A1 (fr) * 2003-11-28 2006-08-16 Kaneka Corporation Composition a effet protecteur des fonctions hepatiques
WO2007148307A1 (fr) * 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions et trousses comprenant de la mélatonine et un constituant chondroprotecteur
EP2471514A1 (fr) * 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi La teneur en eau controllée de granules ou formulations de cetyl myristate et/ou cetyl palmitate
WO2017125919A1 (fr) * 2016-01-18 2017-07-27 My Nutra Ltd. Compositions contenant de la mélatonine
CN113712990A (zh) * 2021-08-04 2021-11-30 北京斯利安健康科技有限公司 一种组合物及其制备方法与应用
US20220031737A1 (en) * 2016-08-08 2022-02-03 Glucare Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
US11351181B2 (en) * 2017-08-08 2022-06-07 James Peter Morrissette Dietary supplement

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048816A1 (fr) * 1997-04-28 1998-11-05 Nutramax Laboratories, Inc. Composes d'aminosucre, de glycosaminoglycane ou du type des glycosaminoglycanes, et s-adenosylmethionine
EP0913155A2 (fr) * 1997-10-24 1999-05-06 Pharma Nord (UK) Ltd. Formulations pharmaceutiques utilisées dans le traitement des affections du foie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998048816A1 (fr) * 1997-04-28 1998-11-05 Nutramax Laboratories, Inc. Composes d'aminosucre, de glycosaminoglycane ou du type des glycosaminoglycanes, et s-adenosylmethionine
EP0913155A2 (fr) * 1997-10-24 1999-05-06 Pharma Nord (UK) Ltd. Formulations pharmaceutiques utilisées dans le traitement des affections du foie

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] HENDERSON ET AL.: "Amino sugar, glycosaminoglycan or glycosaminoglycan-like compounds and S-adenosylmethionine", XP002936272, accession no. STN Database accession no. 1998:719279 *
DATABASE CAPLUS [online] HENRIKSEN B.: "Pharmaceutical formulation for treating liver disorders containing inorganic selenium and vitamins", XP002936273, accession no. STN Database accession no. 1999:297227 *

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092112A1 (fr) * 2001-05-11 2002-11-21 Holford & Associates Limited Supplement oral
WO2003013549A2 (fr) * 2001-08-09 2003-02-20 Degussa Food Ingredients Gmbh Formulation contenant de la (lyso-)phosphatidylserine, servant a prevenir et a traiter des etats de stress chez des homeothermes
WO2003013549A3 (fr) * 2001-08-09 2003-11-06 Degussa Bioactives Gmbh & Co K Formulation contenant de la (lyso-)phosphatidylserine, servant a prevenir et a traiter des etats de stress chez des homeothermes
WO2003041742A1 (fr) * 2001-11-13 2003-05-22 Rudolph Cartwright Composition nutraceutique
US6585998B2 (en) * 2001-11-13 2003-07-01 Rudolph Cartwright Nutraceutical composition
WO2003043608A1 (fr) * 2001-11-22 2003-05-30 Gnosis Srl Procede de preparation de tablettes comprenant de la s-adenosylmethionine
US7087587B2 (en) 2001-11-22 2006-08-08 Gnosis Srl Process for the preparation of tablets comprising s-adenosylmethionine
EP1690533A4 (fr) * 2003-11-28 2009-03-11 Kaneka Corp Composition a effet protecteur des fonctions hepatiques
EP1690533A1 (fr) * 2003-11-28 2006-08-16 Kaneka Corporation Composition a effet protecteur des fonctions hepatiques
WO2007148307A1 (fr) * 2006-06-23 2007-12-27 The Procter & Gamble Company Compositions et trousses comprenant de la mélatonine et un constituant chondroprotecteur
EP2471514A1 (fr) * 2010-12-29 2012-07-04 Deva Holding Anonim Sirketi La teneur en eau controllée de granules ou formulations de cetyl myristate et/ou cetyl palmitate
WO2012089761A1 (fr) * 2010-12-29 2012-07-05 Deva Holding Anonim Sirketi Régulation de la teneur en eau de granules ou de formulations de myristate de cétyle et/ou de palmitate de cétyle
WO2017125919A1 (fr) * 2016-01-18 2017-07-27 My Nutra Ltd. Compositions contenant de la mélatonine
US10675269B2 (en) 2016-01-18 2020-06-09 Trinutra Ltd. Compositions comprising melatonin
US20220031737A1 (en) * 2016-08-08 2022-02-03 Glucare Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
US11351181B2 (en) * 2017-08-08 2022-06-07 James Peter Morrissette Dietary supplement
US11419877B2 (en) * 2017-08-08 2022-08-23 James Peter Morrissette Dietary supplement
CN113712990A (zh) * 2021-08-04 2021-11-30 北京斯利安健康科技有限公司 一种组合物及其制备方法与应用

Also Published As

Publication number Publication date
WO2001026646A8 (fr) 2001-05-17
AU7863400A (en) 2001-04-23

Similar Documents

Publication Publication Date Title
Alok et al. Herbal antioxidant in clinical practice: A review
EP2303302B1 (fr) Préparation permettant de soulager ou prévenir les symptômes associés aux cristaux d'acide urique
US20050202104A1 (en) Method of enhancement of cognitive skills
WO2009079601A1 (fr) Méthodes et systèmes destinés à l'administration sublinguale de guarana
Khan et al. Chamomile tea: herbal hypoglycemic alternative for conventional medicine.
Fugh-Berman The 5-minute herb and dietary supplement consult
WO2001026646A1 (fr) PRODUITS NUTRACEUTIQUES CONTENANT SAMe AINSI QUE DES SUPPLEMENTS ALIMENTAIRES ET LEUR PROCEDE DE FABRICATION ET D'UTILISATION
GB2368012A (en) Preparation for the relief of inflammatory disease
WO2002011744A1 (fr) Capsule renfermant des antioxydants de type opc (oligomeres procyanidoliques ) a base d'extrait de pepins de raisin et son procede de preparation
CA3074541C (fr) Compositions de suppression de l`appetit et methodes connexes
JP2001048802A (ja) 糖尿病に有効な健康補助食品およびその使用方法、並びに糖尿病に有効な食品配合剤
RU2436415C2 (ru) Композиция биологически активных веществ на основе бетулина с регулируемой скоростью высвобождения компонентов для снижения степени алкогольного опьянения, предупреждения и снятия алкогольной интоксикации и похмельного синдрома
EP1677628B1 (fr) Composition destinee a l'activation du systeme immunitaire
RU2189243C1 (ru) Композиции "гинрозин", обладающие общеукрепляющим и адаптогенным действием
RU2321419C1 (ru) ЭКСТРАКТ Cetraria islandica (L.) Ach. СУХОЙ, ТАБЛЕТИРОВАННАЯ ФОРМА
WO2024003560A1 (fr) Composition à base de plantes pour améliorer la récupération et la maintenance de la santé physique et mentale, comprenant l'amélioration de la fonction cognitive ou la prévention du déclin cognitif
EP1457209A1 (fr) Composition contenant des extraits de Panax ginseng et de Paullinia cupana pour améliorer la fonction cognitive
RU2057463C1 (ru) Биологически активная пищевая добавка "женьшень стимул"
US20080279968A1 (en) Composition and method for inducing lipolysis and increasing the metabolism of free fatty acids
SK5336Y1 (en) Food supplement based on silymarin
EP1570751A1 (fr) Composition pour l'activation du système immunitaire
AU2023201650A1 (en) Formulation to aid metabolism and sleep
EP3919050A1 (fr) Composition nutraceutique comprenant limonene et un extrait sec des fibres de cacao pour le traitement de l' obésité
US20230233456A1 (en) Compositions and methods for treating coronavirus
WO2011049484A1 (fr) Agent antioxydant

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: C1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

CFP Corrected version of a pamphlet front page

Free format text: UNDER (54) PUBLISHED TITLE REPLACED BY CORRECT TITLE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP